drugset / Trial / NCT05180162
Imaging of Pathologic Fibrosis Using 68Ga-FAP-2286
Non-randomizedParallel-groupOpen-labelDiagnostic
Summary
This is a single arm prospective pilot trial that evaluates the ability of a novel imaging agent (68Ga-FAP-2286) to identify pathologic fibrosis in the setting of hepatic, cardiac and pulmonary fibrosis. FAP-2286 is a peptide that potently and selectively binds to Fibroblast Activation Protein (FAP). FAP is a transmembrane protein expressed on fibroblasts and has been shown to have higher expression in idiopathic pulmonary fibrosis (IPF), cirrhosis, and cardiac fibrosis.
Timeline
- Start
- 2021-12-09
- Primary completion
- 2024-05-28
- Completion
- 2024-05-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 68Ga-FAP-2286 | Diagnostic / imaging agent | 111 mbq | Intravenous |
| Subject | 68Ga-FAP-2286 | Diagnostic / imaging agent | 296 mbq | Intravenous |